Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Protalix BioTherapeutics Inc (AMEX: PLX) closed at $1.69 in the last session, up 3.68% from day before closing price of $1.63. In other words, the price has increased by $3.68 from its previous closing price. On the day, 0.82 million shares were traded. PLX stock price reached its highest trading level at $1.73 during the session, while it also had its lowest trading level at $1.6193.
Ratios:
We take a closer look at PLX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.54 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.36. For the most recent quarter (mrq), Quick Ratio is recorded 1.27 and its Current Ratio is at 1.98. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 08, 2020, Reiterated its Buy rating but revised its target price to $11 from $3 previously.
On April 17, 2017, Rodman & Renshaw reiterated its Buy rating and also lowered its target price recommendation from $4 to $5.
On April 04, 2016, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $3.50.Rodman & Renshaw initiated its Buy rating on April 04, 2016, with a $3.50 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PLX now has a Market Capitalization of 124440792 and an Enterprise Value of 84818168. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.72 while its Price-to-Book (P/B) ratio in mrq is 3.84. Its current Enterprise Value per Revenue stands at 2.229 whereas that against EBITDA is -6.271.
Stock Price History:
Over the past 52 weeks, PLX has reached a high of $1.90, while it has fallen to a 52-week low of $0.82. The 50-Day Moving Average of the stock is 46.75%, while the 200-Day Moving Average is calculated to be 42.79%.
Shares Statistics:
According to the various share statistics, PLX traded on average about 222.69K shares per day over the past 3-months and 641970 shares per day over the past 10 days. A total of 72.95M shares are outstanding, with a floating share count of 62.97M. Insiders hold about 14.48% of the company’s shares, while institutions hold 5.10% stake in the company. Shares short for PLX as of 1730332800 were 3097650 with a Short Ratio of 13.91, compared to 1727654400 on 3126674. Therefore, it implies a Short% of Shares Outstanding of 3097650 and a Short% of Float of 4.4099998000000005.
